PARIS (dpa-AFX) - Drug makers Regeneron Pharmaceuticals, Inc. (REGN) and
Sanofi (SNY) announced Wednesday that the European Commission has approved
Dupixent (dupilumab) as an add-on maintenance treatment for adults with
uncontrolled chronic obstructive pulmonary disease or COPD characterized by
raised blood eosinophils.

Dupixent has been approved in the European Union as the first-ever targeted
therapy for patients with COPD, a respiratory disease. The EC is the first
regulatory authority in the world to approve Dupixent for adults with
uncontrolled COPD with raised blood eosinophils. The companies noted that
additional submissions are under review with other regulatory authorities around
the world, including in the U.S., China and Japan.

The EU approval was based on two landmark Phase 3 BOREAS and NOTUS trials. The
data showed that Dupixent significantly reduced exacerbations, improved lung
function and also improved health-related quality of life.

Safety results in both trials were generally consistent with the known safety
profile of Dupixent in its approved indications.

Regeneron and Sanofi said the approval covers patients already on a combination
of an inhaled corticosteroid or ICS, a long-acting beta2-agonist or LABA and a
long-acting muscarinic antagonist or LAMA, or on a combination of a LABA and a
LAMA if ICS is not appropriate.

Paul Hudson, Chief Executive Officer at Sanofi, said, 'With today's approval of
Dupixent, we can change the treatment landscape for the more than 200,000
patients throughout the EU living with uncontrolled COPD with raised blood
eosinophils. We look forward to working with other regulators around the world
as quickly as possible to bring this novel treatment approach to patients in
more countries.'

The latest approval represents the sixth approved indication for Dupixent in the
EU and seventh approved indication globally.

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX